12:00 AM
 | 
Dec 11, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

H376/95: Phase II

In a 600-patient Phase II study comparing H376/95 to Aventis S.A.'s Lovenox enoxaparin low molecular weight heparin, the incidence of VTE was...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >